Hvivo strikes £11.5m RSV contract with existing client

Contract research organisation Hvivo has struck a £11.5m Respiratory Syncytial Virus contract with an "existing top-tier global pharmaceutical client".

Hvivo said on Tuesday that it will test the unnamed client's antiviral candidate using its RSV Human Challenge Study Model, a Phase 2a randomised, double-blinded placebo-controlled human challenge trial.

The AIM-listed group stated the study was scheduled to commence in H225 at its state-of-the-art quarantine facilities in Canary Wharf, with revenue expected to be recognised across 2025 and 2026.

Chief executive Yamin Khan said: "This contract further demonstrates the trust and confidence that leading pharmaceutical companies place in Hvivo's human challenge study models. We are proud to work with four of the top-ten global pharmaceutical companies to address unmet medical need in infectious and respiratory diseases.

"Our unique and established RSV model can provide valuable data on a candidate's safety, pharmacokinetics, and efficacy, reducing the risks associated with later-stage clinical development and accelerating the pathway to market."

As of 0920 GMT, Hvivo shares were up 4.16% at 22.13p.

Reporting by Iain Gilbert at Sharecast.com